| diabetes type 2 | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Voglibose Ph-3, 2009 | voglibose vs placebo | diabetes 0.46 [0.34; 0.64] | | |
| Trial | Treatments | Patients | Method |
|---|
| Voglibose Ph-3, 2009 | voglibose 0.2 mg three times daily (n=897) vs. placebo (n=881) | patients with impaired fasting glucose | double blind Parallel groups Sample size: 897/881 Primary endpoint: type 2 diabetes mellitus FU duration: 4.01 years |
|
| impaired fasting glucose | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Voglibose Ph-3, 2009 | voglibose vs placebo | diabetes 0.46 [0.34; 0.64] | | |
| Trial | Treatments | Patients | Method |
|---|
| Voglibose Ph-3, 2009 | voglibose 0.2 mg three times daily (n=897) vs. placebo (n=881) | patients with impaired fasting glucose | double blind Parallel groups Sample size: 897/881 Primary endpoint: type 2 diabetes mellitus FU duration: 4.01 years |
|
